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Abstract
Dopamine (DA) release in the CNS is critical for motor control and motivated behaviors. Dysfunction of its regulation is
thought to be implicated in drug abuse and in diseases such as schizophrenia and Parkinson’s. Although various potassium
channels located in the somatodendritic compartment of DA neurons such as G-protein-gated inward rectifying potassium
channels (GIRK) have been shown to regulate cell firing and DA release, little is presently known about the role of potassium
channels localized in the axon terminals of these neurons. Here we used fast-scan cyclic voltammetry to study electrically-
evoked DA release in rat dorsal striatal brain slices. We find that although G-protein-gated inward rectifying (GIRK) and ATP-
gated (KATP) potassium channels play only a minor role, voltage-gated potassium channels of the Kv1 family play a major
role in regulating DA release. The use of Kv subtype-selective blockers confirmed a role for Kv1.2, 1.3 and 1.6, but not Kv1.1,
3.1, 3.2, 3.4 and 4.2. Interestingly, Kv1 blockers also reduced the ability of quinpirole, a D2 receptor agonist, to inhibit evoked
DA overflow, thus suggesting that Kv1 channels also regulate presynaptic D2 receptor function. Our work identifies Kv1
potassium channels as key regulators of DA release in the striatum.
Citation: Martel P, Leo D, Fulton S, Be ´rard M, Trudeau L-E (2011) Role of Kv1 Potassium Channels in Regulating Dopamine Release and Presynaptic D2 Receptor
Function. PLoS ONE 6(5): e20402. doi:10.1371/journal.pone.0020402
Editor: Colin Combs, University of North Dakota, United States of America
Received March 10, 2011; Accepted April 25, 2011; Published May 27, 2011
Copyright:  2011 Martel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grant MOP-49591 from the Canadian Institutes of Health research (CIHR) to LET. LET was supported by a senior scholar
award from the Fonds de la Recherche en Sante ´ du Que ´bec (FRSQ) and also receives support through an infrastructure grant provided by the FRSQ to the Groupe
de Recherche sur le Syste `me Nerveux Central. PM was supported in part by a COPSE fellowship of the Universite ´ de Montre ´al. MB was supported by a fellowship
from the FRSQ. SF was supported by a National Science and Engineering Research Council (NSERC) postdoctoral fellowship. DL was supported by a postdoctoral
fellowship (PDRF) from the Department of Foreign Affairs and International Trade of Canada and by a postdoctoral fellowship from the Fonds de la Recherche en
Sante ´ du Que ´bec (FRSQ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: louis-eric.trudeau@umontreal.ca
Introduction
Dopamine (DA) release in the CNS is critical for motor control by
basal ganglia circuits and a dysfunction of its regulation is thought to
be implicated in adaptations of the brain in response to drugs of abuse
as well as in diseases such as schizophrenia and Parkinson’s. A number
of control mechanisms regulating DA release have been identified. For
example, DA has long been known to regulate its own release through
the activation of autoreceptors [1]. The activation of D2 autoreceptors
located on the soma and dendrites of DA neurons inhibits cell firing
[2,3,4] and decreases somatodendritic DA release [5,6,7]. It can also
activate DA reuptake [8,9] and inhibit DA synthesis [10,11,12,13].
The hyperpolarizing effect of somatodendritic D2 autoreceptors has
been proposed to occur principally through activation of G-protein-
gated inward rectifying K
+ channels (GIRKs) [14,15,16]. Autorecep-
tors are also present on the axon terminals of DA neurons [17,18].
Electrically-evoked DA release in the striatum can be inhibited by D2-
type receptor agonists and enhanced by D2-type receptor antagonists
[19,20]. A specific role for the D2-short splice variant of the D2
receptor in this process was confirmed by the near absence of
autoreceptor function in D2 knockout mice [21,22,23,24], and the
maintenance of D2-autoreceptor function in D2-long knockout mice
[21] and in D3 knockout mice [25].
The critical role of somatodendritic GIRK channels in
regulating DA release raises the question as to whether such
channels or other types of potassium channels are also present on
dopaminergic axon terminals in the striatum and are involved in
regulating DA release. Although GIRK channels are usually not
found on axon terminals [26], there is evidence for the presence of
voltage-gated Kv-type K
+ channels [27] and of KATP channels
[28,29]. For example, using a striatal slice preparation, Cass et al.
showed that the wide-spectrum Kv channel blockers 4-aminopyr-
idine (4-AP) and tetraethylammonium (TEA) enhance electrically-
evoked [
3H]DA release [27]. However, the Kv channel subtype
that is targeted by 4-AP in the terminals of DA neurons is
currently unknown. In the present work, we took advantage of
selective Kv neurotoxins and fast-scan cyclic voltammetry in a rat
striatal brain slice preparation to directly examine the role of Kv
potassium channel subtypes in controlling electrically-evoked DA
release. We find an important role of Kv1-type potassium channels
and show in addition that these channels act as a gating
mechanism to influence presynaptic D2 function.
Methods
Ethics Statement
All experiments were approved by the Universite ´ de Montre ´al’s
animal ethics committee (protocol #10-122). All efforts were made
to minimize the number of animals used and their suffering.
Brain slice preparation and solutions
Four to six weeks old male and female Sprague-Dawley rats
were anesthetized with halothane and quickly decapitated.
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20402Coronal striatal brain slices of 300 mm (Bregma 1.70 to 0.48 mm)
[30] were prepared with a VT1000S vibratome (Leica Micro-
systems Inc., Nussloch, Germany) in ice-cold (0 to 4uC) artificial
CSF (ACSF) containing (in mM): 125 NaCl, 26 NaHCO3, 2.5
KCl, 2.4 CaCl2, 1.3 MgSO4, 0.3 KH2PO4 and 10 D-Glucose;
adjusted to 300 mOsm/kg and saturated with 95% O2-5% CO2.
Slices were then kept in ACSF at room temperature and allowed
to recover for at least 1 hour. For recordings, slices were put in a
custom-made recording chamber superfused with ACSF (1 ml/
min) maintained at 32uC with a TC-324B single channel heater
controller (Warner Instrument Inc., Hamden, CT, USA). All
drugs and chemicals were obtained from Sigma-Aldrich Canada
(Oakville, ON). Glibenclamide was purchased from Tocris
(Ellisville, MO). All toxins were obtained from Alomone labs
(Jerusalem, Israel). All drugs and toxins were kept frozen in
individual aliquots and thawed just before use. The pH of solutions
containing the K
+ channel antagonists 4-AP and TEA was
adjusted to 7.4 prior to use.
Electrochemical recordings and electrical stimulation
Electrically-evoked, action potential-induced DA release was
measured by fast-scan cyclic voltammetry (FSCV) using a 5 mm
diameter carbon-fiber electrode placed into the dorsal striatum
,100 mm below the surface. Carbon-fiber electrodes were
constructed according to Kawagoe et al. [31]. Briefly, carbon fibers
(Cytec Industries Inc., NJ, USA) approximately 5 mm in diameter
were aspirated into ethanol-cleaned glass capillaries (1.2 mm 6
0.68 mm, 4 inches long; A-M Systems, WA, USA). The glass
capillaries were then pulled using a P-2000 micropipette puller
(Sutter Instruments, Novato, USA), dipped into 90uC epoxy for
30 sec (Epo-Tek 301, Epoxy Technology, MASS, USA) and
cleaned in hot acetone for 3 seconds. The electrodes were heated
at 100uC for 12 hours and 150uC for 5 days. Prior to use, electrodes
were cleaned with agitated isopropyl alcohol for 15 min to promote
greater sensitivity [32]. Carbon fibers were cut using a nu11 scalpel
blade under direct visualization to obtain maximal basal currents of
100 to 180 nA. Electrodes were finally selected for their DA
sensitivity using in vitro calibration with 1 mM DA in ACSF.
The potential of the carbon fiber electrode was scanned at a rate
of 300 V/s according to a 10 ms triangular voltage wave (2400 to
1000 mV vs Ag/AgCl) with a 100 ms sampling interval using an
Axopatch 200B amplifier (Axon Instruments, Union City, CA) or
a Warner PC-501A (Warner Instrument Inc., Hamden, CT, USA)
(Fig. 1B). Data were acquired using a DigiData 1200B analog to
digital board converter (Axon Instruments) connected to a
Compaq Pentium III personal computer using Clampex 9.2
(Axon Instruments). Single pulse stimulations (400 mA; 1 ms) were
generated by a S-900 stimulator (Dagan Corporation, Minneap-
olis, MN) every 2 min to electrically evoke DA release in the dorsal
striatum. The tips of the bipolar electrode (Plastics One, Roanoke,
VA) were separated by approximately 100 to 150 mm and were
gently placed on the surface of the slice using a micromanipulator.
Under these conditions, DA release was tetrodotoxin-sensitive and
Ca
2+ dependent (data not shown).
Data analysis
Channel blockers were superfused for 30 min, except where
otherwise stated. Quinpirole was applied by superfusion for 4 min
and the effect of this D2 agonist was evaluated at its peak. This
short quinpirole application time may lead to underestimation of
maximal effects and apparent IC50, but provides a reproducible
effect. Control experiments with quinpirole alone were performed
in parallel to experiments evaluating the effect of blockers. The
effects of quinpirole in the presence of the various blockers were
always compared to control experiments performed during the
same series of experiments. In experiments in which K
+ channel
blockers were applied, a stable 10 min control period was first
obtained followed by 30 min bath application of the blockers. The
effect of drugs and toxins on DA release was determined by
normalizing values against their own control period which
represented the first 10 min of stable recording before drug
application. Statistical analyses were conducted by comparing the
means of the last 10 min of blocker application to the mean of the
last 10 min of control recordings. Results are shown as mean 6
SEM. The sample size is shown as n=(x;y), where x refers to the
number of slices and y the number of animals. Only one
experiment was performed on each slice. Unpaired t-tests were
used when comparing two groups while one-way ANOVAs with
post hoc comparisons (Tukey test) were used when comparing
multiple groups of data. Significance levels used in figures are
shown as: single asterisk (*) = p,0.05, double asterisks (**) = p,0.01
and triple asterisks (***) = p,0.001.
Results
Broad-spectrum potassium channel blockers enhance DA
release
DA release was electrically-evoked with single pulses every
2 min in striatal brain slices from 4 to 6 weeks old Sprague-Dawley
rats and measured using FSCV at 300 V/S (Fig. 1A and 1B).
Evoked DA overflow in control conditions reached ,1 mM
(Fig. 1C). The detection limit due to experimental noise was
approximately 0.06 mM (n=19;7). While differences in the
nigrostriatal pathway of female and male rats have been previously
reported [33,34], we didn’t find any statistical difference in the
maximal amount of DA release evoked by single pulse in males
(1.0460.09 mM; n=23) and females (0.9460.08 mM; n=28)
(data not shown; p.0.05). Recovery of extracellular DA levels,
reflecting mostly reuptake, was rapid, requiring no more than
1 sec (Fig. 1C). Evoked DA overflow was stable over time with a
mean rundown of 6.962.4% (n=8;6) over a period of 40 min of
control recording (see control trace in Fig. 2C).
Following this validation of our experimental conditions, we
next evaluated the role of potassium channels using 4-AP and
TEA, two broad-spectrum potassium channel blockers (Fig. 2).
After a 30 min application of 100 mM 4-AP, DA overflow
increased by 68.068.3% (n=10;4) (Fig. 2A, 2C). At 1 mM, 4-
AP rapidly increased DA overflow by ,80%, but a significant
rundown appeared, and after 30 min, DA overflow was maximally
increased by 43.465.6% (data not shown, n=7;3). At these two
doses, the effect of 4-AP was statistically different from the basal
rundown (p,0.001 for both) and the difference between the doses
was statistically significant (p,0.05). At a dose of 10 mM, 4-AP
was detrimental to slice survival, as revealed by the rapid rundown
of electrically-evoked DA overflow (data not shown, n=2;1).
Considering toxicity at 10 mM and a rundown effect at 1 mM, all
further experiments were thus performed with 100 mM 4-AP.
At 1 mM, TEA increased DA overflow by 12.966.0%, which
was not different from basal rundown (data not shown, n=6;3,
p.0.05). Surprisingly, at 10 mM, TEA caused a very large, yet
stable increase of 792.9688.0% (n=10;3, p,0.001) (Fig. 2B, 2D).
This effect is not likely due to a change in osmolarity, since
addition of 20 mOsm of sucrose in ACSF had no effect on
electrically-evoked DA overflow (data not shown). Moreover, this
effect was not due to an increase in electrode sensitivity for DA,
because in-vitro calibration using 1 mM DA in the presence of
10 mM TEA did not reveal any change in comparison to control
conditions without TEA (data not shown).
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release induced by 10 mM TEA is that enhanced depolarization of
axonterminalsmayoccurundersuchconditions,perhapsleadingto
the recruitment of additional synaptic and extra-synaptic voltage-
gated Ca
2+ channels. To address this issue, we first determined the
subtype of voltage-gated Ca
2+ channels required for electrically-
evoked DA release under our experimental conditions. Although
20 mM nifedipine, a L-type Ca
2+ channel blocker, and 200 nM v-
agatoxin IVA, a blocker which is specific for P/Q-type Ca
2+
channels at this concentration, did not significantly reduce DA
release (12.361.3% decrease; n=6;3; p.0.05 and 14.363.0%
decrease; n=6;2; p.0.05, respectively) (results not shown), the N-
type Ca
2+ channel blocker v-conotoxin GVIA (ConoTX) almost
totally blocked DA release at 1 mM (91.761.2% decrease, ; n=5;2 ;
p,0.001) (Fig. 2E). We next evaluated the effect of ConoTX after
pre-application of 100 mM 4-AP or 10 mM TEA. We reasoned that
if non-N-type extrasynaptic Ca
2+ channels were recruited, this
should result in an increase in the fraction of the release that is
resistant to ConoTX block. After a 30 min pre-application of
100 mM4-AP,ConoTX(1 mM)produced aslightlyreduced butstill
strong decrease of DA release by 74.662.2% (n=6;3), which was
statistically different from the effect of ConoTX alone (p,0.001)
(Fig. 2E). However, in the presence of 10 mM TEA, ConoTX
(1 mM) failed to significantly inhibit evoked DA overflow as
91.462.9% of the signal still remained (n=6;2) (Fig. 2F). Overall,
these data show that although 4-AP increases DA release by about
70%, this extra release remains largely dependent on N-type
calcium channels. On the contrary, the large increase produced by
TEA appears to be dependent on additional, perhaps extra-
synaptic, Ca
2+ channels that are insensitive to the N-type Ca
2+
channelantagonistandthatmightberecruitedbynon-physiological
depolarization of axon terminals.
Kv subunit blockers increase electrically-evoked DA
overflow
At the concentration we used, 4-AP blocks several voltage-
dependent potassium channels containing Kv1.x and Kv3.x
subunits [35]. However, considering previous reports suggesting
the presence of Kv1-family potassium channels in various axon
terminals in the CNS [36], we hypothesized that Kv1 channels
could play a particularly important role. To discriminate between
the various Kv subtypes, we used several toxins shown to
specifically inhibit different Kv channels (Fig. 3). At 100 nM, r-
Margatoxin (MgTX), a blocker of Kv1.3 channels [37], increased
DA levels by 25.864.9% (n=5;3, p,0.01) (Fig. 3A, 3B, 3C). At
50 nM, r-Tityustoxin Ka (TiTX), a specific Kv1.2 subtype blocker
[38], increased DA levels by 29.163.2% (n=6;2, p,0.001)
(Fig. 3C). At 100 nM, dendrotoxin-K (DTX-K), a specific Kv1.1
subtype blocker [39], caused no significant change in DA levels
compared to rundown (14.063.9% decrease, n=6;3, p.0.05).
Finally, at 100 nM, a-Dendrotoxin (a-DTX), a specific Kv1.1, 1.2
and 1.6 subtype blocker [39], produced a variable increase in DA
levels which did not reach statistical significance (15.565.6%
increase, n=6;4, p=0.08).
Figure 1. Fast-scan cyclic voltammetry in the rat dorsolateral striatum. (A) DA release was electrically-evoked with a bipolar stimulating
electrode and recorded with FSCV using a 5 mm carbon-fiber recording electrode placed in the dorsolateral striatum. (B) Background-subtracted
traces showing oxydo-reduction of DA recorded with a triangular voltage ramp (bottom trace). In vitro calibration with 1 mM DA (top recording) was
used to convert the signal to DA concentrations. DA overflow was electrically-evoked with a 400 mA/1 ms single stimulation (middle trace).
Quinpirole (1 mM) reduced DA overflow more than 75%. (C) Example of DA overflow kinetics. Each dot represents the peak amplitude of each
oxidation traces obtained at intervals of 100 ms after a 400 mA/1 ms single stimulation. Abbreviations: aca, anterior commissure anterior part; CPu,
Caudate putamen; Quinp, Quinpirole.
doi:10.1371/journal.pone.0020402.g001
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PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20402Figure 2. Effect of broad-spectrum potassium channel blockers on evoked DA overflow. (A) A 30 min perfusion of the broad-spectrum
potassium channels blocker 4-AP (100 mM) (n=10;4) increased DA overflow kinetics compared to control (n=8;6). Data were normalized to the first 6
recordings (10 min) of their respective control period (means 6 SEM). (B) A 30 min perfusion of the broad-spectrum potassium channels blocker TEA
(10 mM) (n=10;3) drastically increased DA overflow kinetics compared to control (n=8;6). Data were normalized to the first 6 recordings (10 min) of
their respective control period (means 6 SEM). (C) Time-course of the effect of a 30 min application of 100 mM 4-AP (n=10;4) in comparison to
control (n=8;6). DA was electrically evoked at intervals of 2 min. Each group is normalized to the first 6 recordings (10 min) of its respective control
period and graphically plotted against time (means 6 SEM). After 10 min of stable recordings, 4-AP was superfused for 30 min. (D) Time-course of the
effect of a 30 min application of 10 mM TEA (n=10;3) in comparison to control (n=8;6). (E) After a 30 min application of 100 mM 4-AP, 1 mM ConoTX
was applied and caused a , 90% decrease in evoked DA release. (F) After a 30 min application of 10 mM TEA, 1 mM ConoTX was applied and failed to
inhibit DA overflow. Abbreviations: 4-AP, 4-aminopyridine; TEA, tetraethylammonium; ConoTX, v-conotoxin GVIA.
doi:10.1371/journal.pone.0020402.g002
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regulating axonal DA release, we also tested some toxin
combinations. A 30 min application of both 50 nM TiTX and
100 nM MgTX increased DA levels by 21.6611.5% (n=4;3,
p,0.05) (Fig. 3C), while a 30 min application of both a-DTX
(100 nM) and MgTX (100 nM) increased DA levels by
71.4615.7% (n=4;2, p,0.001) (Fig. 3A, 3B, 3C). Together,
these data suggest a role for Kv1.2, Kv1.3 and Kv1.6 in regulating
DA release.
Because 4-AP can also block some Kv3.x-containing potassium
channels, we also evaluated the effect of blood depressing
substance I (BDS-I), a blocker of Kv3.4 in the low nanomolar
Figure 3. Effect of selective Kv potassium channel subunit blockers on evoked DA overflow. (A) Summary traces showing the average
electrically-evoked DA overflow in response to single electrical pulses after 30 min perfusion with 100 nM MgTX (n=5;3) or a combination of both
100 nM MgTX and 100 nM a-DTX (n=4;2), in comparison to control (n=8;6). Data were normalized to the first 6 recordings (10 min) of their
respective control period (means 6 SEM). The effect of other Kv subunits blockers is omitted for clarity. (B) Time-course of the experiment shown in
A. DA was electrically evoked at intervals of 2 min. Each group is normalized to the first 6 recordings (10 min) of its respective control period and
graphically plotted against time (means 6 SEM). After 10 min of stable recordings, drugs were superfused for 30 min. Apparent equilibrium was
reached for all Kv channel blockers after 20 min of application. The effect of others Kv channel blockers is omitted for clarity. (C) Histogram showing
the mean increase in electrically-evoked DA overflow during the last 10 min of application of several Kv potassium channel blockers: control (n=8;6),
100 mM 4-AP (n=10;4), 100 nM MgTX (n=5;3), 50 nM TiTX (n=6;2), 100 nM DTX-K (n=6;3), 100 nM a-DTX (n=6;4), 50 nM TiTX + 100 nM MgTX
(n=4;3), 100 nM a-DTX + 100 nM MgTX (n=4;2), 500 nM BDS-I (n=6;2) and 100 nM HetTX (n=6;2). * p,0.05, ** p,0.01, *** p,0.001. Abbreviations:
4-AP, 4-aminopyridine; a-DTX, a-dendrotoxin; MgTX, rMargatoxin; TiTX, rTityustoxin Ka; DTX-K, dendrotoxin-K; BDS-I, blood depressing substance I;
HetTX, rHeteropodatoxin-2.
doi:10.1371/journal.pone.0020402.g003
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e20402Figure 4. D2 receptor activation dose-dependently inhibits dopamine overflow. A) DA was electrically-evoked at intervals of 2 min. The peak
amplitude of DA overflow is normalized to the average amplitude of the first 6 recordings (10 min) of the control period and graphically plotted against
time (means 6 SEM). The control trace (n=8;6) shows that evoked DA overflow was stable over time. Quinpirole was applied for 4 min (represented by
the gray bar) at 3 different doses. Drug effects were measured at their peak (rectangle at 16 min). Sulpiride (5 mM) blocked entirely the effect of
quinpirole. (B) Histogram showing the peak effect of quinpirole on DA overflow. A one-way ANOVA was used to compare groups. The effect of
quinpiroleat0.1 mM (n=5;4),0.5 mM (n=7;4) and1 mM (n=27;18) was significant. TheD3receptor subtypeblocker, GR103,691, onlyreduced quinpirole
effect at the non-selective dose of 1 mM (n=4;2), while its effect was non-significant at 100 nM (n=6;2). Used at 1 mM, L741,626, a D2 subtype selective
blocker, significantly reduced the effect of quinpirole (n=6;2). Sulpiride (5 mM), a broad-spectrum D2-family receptor antagonist, complety blocked the
effect of quinpirole (n=3;2). *** p,0.001 Abbreviations: Q, Quinpirole; Quinp, Quinpirole; GR, GR103,691; L, L741,626, Sulp, Sulpiride.
doi:10.1371/journal.pone.0020402.g004
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[40]. At 500 nM, BDS-I caused no significant change in DA levels
compared to rundown (13.364.0% decrease) (n=6;2, p.0.05)
(Fig. 3C). As a negative control, we also evaluated the effect of
100 nM, r-Heteropodatoxin-2 (HetTX), a specific blocker of
Kv4.2 channels, a K
+ channel subunit known to be usually
restricted to the somatodendritic compartment of neurons and that
is not expressed by DA neurons [41]. HetTX caused no significant
change in DA levels compared to rundown (13.462.2% decrease)
(n=6;2, p.0.05) (Fig. 3C).
Kv1 channels regulate D2-mediated inhibition of DA
release
Considering the important role of Kv1 channels in regulating
DA release, identified in the present report, and the existence of
previous reports suggesting reduced autoreceptor function in the
presence of 4-AP [18,27], we next hypothesized that Kv1 channels
act as mediators of presynaptic D2 function or as a gating
mechanism controlling the effectiveness of this receptor, perhaps
through regulation of terminal polarity.
We first confirmed that, as expected, the D2 agonist quinpirole
decreased electrically-evoked DA release in a dose-dependent
manner (Fig. 4A and 4B). A 4 min application of 0.1 mM, 0.5 mM
or 1 mM quinpirole decreased DA levels by 27.562.7% (n=7;5,
p,0.001), 46.763.8% (n=7;4, p,0.001) and 77.561.7%
(n=27;18, p,0.001), respectively. Again, we found no sex
difference in the effect of 1 mM quinpirole in males (75.461.5%
decrease; n=11;7) and females (73.763.4% decrease; n=6;3)
(data not shown; p.0.05). Because quinpirole can bind to the D3
receptor subtype in addition to the D2 subtype, we evaluated
whether the effect of quinpirole was reduced by GR103,691, a D3-
subtype preferring antagonist and L741,626, a D2-subtype
preferring antagonist. We found that at a concentration of
100 nM, known to occupy a majority of D3 receptors (Murray
et al., 1995; Audinot et al., 1998), a 20 min pre-application of
GR103,691 failed to significantly reduce the effect of 1 mM
quinpirole on DA overflow evoked by single pulses (69.264.7%
decrease; n=6;2; p.0.05) (Fig. 4B). At a concentration of 1 mM,
which would be predicted to block a subset of D2 receptors in
addition to D3 receptors, GR103,691 caused a significant
reduction in the effect of quinpirole (44.365.5% decrease;
n=4;2; p,0,001) (Fig. 4B). In comparison, at a concentration of
100 nM, known to occupy a significant proportion of D2 but not
D3 receptors (Bowery et al., 1996; Pillai et al., 1998), L741,626
significantly reduced the effect of quinpirole (49.866.0% decrease;
n=6;2), which was different from the effect of quinpirole alone;
p,0.001) (Fig. 4B). Complete block of the effect of quinpirole
could be achieved using sulpiride (5 mM), a broad-spectrum D2-
family receptor antagonist (6.665.1% decrease; n=3;2, p,0.001)
(Fig. 4A). However, none of the three receptor antagonists by
themselves had a significant effect on DA overflow: they caused a
decrease of 6.262.3% (sulpiride 5 mM), 11.361.5% (GR103,691
1 mM) or 16.463.4% (L741,626 100 nM) after 10 min, which was
not statistically different from the basal rundown (data not shown;
p.0.05). These results indicate that electrically-evoked DA
overflow under our conditions can be inhibited by a D2
receptor-mediated mechanism in a dose-dependent manner under
conditions where there is no detectable basal activation of these
receptors following single pulse stimulation. These observations
confirm previous findings [5,25,42].
We next evaluated the role of K
+ channels in D2-mediated
inhibition of DA overflow. After a 30 min pre-application of
100 mM 4-AP, quinpirole (1 mM) decreased DA release by only
41.161.5% (n=6;2) (Fig. 5C). This effect was statistically different
from that induced by quinpirole alone (p,0.001). After a 30 min
pre-application of 1 mM or 10 mM TEA, quinpirole (1 mM)
decreased DA release by 62.963.4% (n=6;3) and 12.163.9%
(n=6;2) respectively (data not shown), a significant reduction in
comparison to the effect of quinpirole alone (p,0.01 and p,0.001
respectively).
To narrow down the role of different Kv subunits in regulating
D2-mediated inhibition of DA release, we measured the effect of
quinpirole (1 mM) after a 30 min pre-application of subtype-
specific potassium channel toxins (Fig. 5). After pre-treatment with
100 nM a-DTX, a Kv1.1, 1.2 and 1.6 blocker, quinpirole
decreased DA release by 53.263.9%, an effect that was
statistically different from the effect of quinpirole alone (n=6;4,
p,0.001). In the presence of 100 nM MgTX, a Kv1.3 blocker,
quinpirole decreased DA release by 64.161.8%, which was again
statistically different from the effect of quinpirole alone (n=5;3,
p,0.01). In the presence of 50 nM TiTX, a kv1.2 blocker,
quinpirole decreased DA release by 60.165.1%, which was
statistically different from the effect of quinpirole alone (n=6;2,
p,0.01). In the presence of 100 nM DTX-K, a Kv1.1 blocker,
quinpirole decreased DA release by 71.762.1%, which was not
statistically different from the effect of quinpirole alone (n=6;3,
p.0.05).
In the presence of both 50 nM TiTX and 100 nM MgTX,
quinpirole decreased DA release by 46.162.7%, which was
statistically different from the effect of quinpirole alone (n=6;4,
p,0.001). Finally, with a 30 min pre-application of a combination
of 100 nM MgTX and 100 nM a-DTX, quinpirole decreased DA
release by 43.962.8%, an effect that was statistically different from
the effect of quinpirole alone (n=6;3; p,0.001). As expected, pre-
application of 500 nM BDS-I or 100 nM HetTX did not cause
any significant change in quinpirole-induced inhibition of DA
release (76.362.1% decrease, n=6;2 and 94.260.8% decrease,
n=6;2; p.0.05 for both). Overall, these results suggest that
Kv1.2, Kv1.3 and Kv1.6 potassium channel subtypes can regulate
D2-mediated inhibition of DA release while Kv1.1, Kv3.1, Kv3.2,
Kv3.4 and Kv4.2 are unlikely to be involved.
Although unlikely in the case of voltage-gated channels such
as those of the Kv1 family, potassium channel blockers could
theoretically depolarize axon terminals, which could perhaps
lead to partial inactivation of sodium or calcium channels. This
could represent an alternative explanation of our finding that
potassium channel blockers reduce the effect of the D2 agonist
quinpirole. To evaluate this possibility, we exposed slices to
ACSF containing 8.5 mM extracellular potassium (instead of
2.8 mM), thus directly causing a modest depolarization of
dopaminergic terminals (estimated by patch-clamping to be of a
magnitude of less than 5 mV; results not shown). Validating the
effectiveness of the depolarization, we noted that after 20 min of
elevated potassium, single-pulse evoked DA overflow was
reduced by 37.1610.4%, which was statistically more than the
basal rundown (n=4;2; p,0.001). However, under these
conditions, the ability of quinpirole to reduce DA overflow
was not significantly reduced (85.063.2% decrease; n=4;2;
p.0.05). These results argue that potassium channel blockers
do not simply reduce the effect of quinpirole through a non-
specific depolarization of terminals.
Evaluation of the role of GIRK and KATP channels in
regulating DA release
Considering that even a broad-spectrum Kv potassium channel
blocker such as 4-AP only blocked approximately 50% of the
effect of quinpirole on evoked DA overflow, it is possible that
other classes of potassium channels are also involved. Considering
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somatodendritic compartment of DA neurons and their regula-
tion through D2 receptors [43,44], we next evaluated the effect of
barium, a blocker of GIRK channels, and of glibenclamide, a
blocker of KATP channels. Applied alone, 1 mM barium
decreased evoked DA overflow by 7.162.2% (Fig. 6), which
was not statistically different from spontaneous rundown (n=7;3;
p.0.05). Glibenclamide (3 mM) gave similar results (Fig. 6); a
rundown of 11.663.4%, which was not statistically different from
spontaneous rundown (n=7;4; p.0.05). Moreover, a KATP
channels opener, diazoxide (30 mM), had no significant effect on
evoked DA overflow (decrease of 13.661.6%, which was not
statistically different from spontaneous rundown) (Fig. 6B;
n=6;2; p.0.05).
We also evaluated the effect of the D2 agonist quinpirole in the
presence of these two antagonists. After a 30 min pre-application
Figure 5. Regulation of D2-mediated inhibition of DA release by Kv1 potassium channels. (A) Applied alone for 4 min, 1 mM quinpirole
(n=27;18) induced a large inhibition of evoked DA overflow compared to control (n=8;6). Pre-application (30 min) of 100 nM MgTX (n=5;3) or a
combination of both 100 nM MgTX and 100 nM a-DTX (n=4;2) reduced the effect of quinpirole. Data were normalized to the first 6 recordings
(10 min) of their respective control period (means 6 SEM). The effect of others Kv subunits blockers is omitted for clarity. (B) Time-course of the
experiment shown in A. DA was electrically-evoked at intervals of 2 min. Each group was normalized to the first 6 recordings (10 min) of its respective
control period (means 6 SEM). The maximal effect of quinpirole was detected after 6 min (represented by the rectangle). (C) Histogram showing the
ability of potassium channel blockers selective for various Kv subtypes to reduce the effect of quinpirole (1 mM) on evoked DA overflow: quinpirole
alone (n=27;18, represented by the black doted bar), 4-AP (n=6;2), 100 nM a-DTX (n=6;4), 100 nM MgTX (n=5;3), 50 nM TiTX (n=6;2), 100 nM DTX-
K (n=6;3), 50 nM TiTX + 100 nM MgTX (n=6;4), 100 nM a-DTX + 100 nM MgTX (n=6;3), 500 nM BDS-I (n=6;2), 100 nM HetTX (n=6;2) and high
concentration of potassium (n=4;2). * p,0.05, ** p,0.01, *** p,0.001. Abbreviations:K
+, potassium; 4-AP, 4-aminopyridine; a-DTX, a-dendrotoxin;
MgTX, rMargatoxin; TiTX, rTityustoxin Ka; DTX-K, dendrotoxin-K; BDS-I, blood depressing substance I; HetTX, rHeteropodatoxin-2; quinp, quinpirole.
doi:10.1371/journal.pone.0020402.g005
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78.264.9%, which was not statistically different from the effect of
quinpirole alone (data not shown, n=7;3; p.0.05). In the
presence of 3 mM glibenclamide, quinpirole (1 mM) decreased
DA release by 64.567.6%, which represented a small but
statistically significant decrease compared to the effect of
quinpirole alone (data not shown, n=6;3; p,0.05). We conclude
that while GIRK channels do not play any apparent role in
regulating basal, electrically-evoked DA release under our
experimental conditions, KATP channels may contribute to a
minor proportion of the D2-mediated inhibition of DA release.
Discussion
A better understanding of the regulatory mechanisms and ionic
channels that control DA release is of major interest. Little is
presently known concerning the potassium channels that are
present in the axon terminals of DA neurons in the striatum. Here
we provide an evaluation of the role of Kv1 potassium channels in
the regulation of DA release. We show that Kv1.2, Kv1.3 and
Kv1.6 are likely to be key players in regulating axonal DA release.
We also show that these channels act as mediators or regulators of
presynaptic D2 receptor function.
Potassium channel regulation of DA release
A number of potassium channels have been demonstrated to be
present in the somatodendritic compartment of DA neurons. This
includes GIRKs [43,45,46,47,48], Ca
2+-activated potassium
channels [49,50], KATP channels [28,29] and various voltage-
dependent potassium channels mediating rapidly-inactivating and
delayed potassium current [51]. For example, D2 receptors can
activate potassium conductances in the somatodendritic compart-
ment of DA neurons that are compatible with the properties of
GIRK channels (Lacey et al. 1987, Uchida et al. 2000). In cell
lines and in brain slices, D2 receptors have been confirmed to
couple to the GIRK2 potassium channels, the only GIRK subtype
expressed by DA neurons [43,45,46,47,48]. It has been generally
assumed that GIRK channels are also present in the axon
terminals of DA neurons and that they are required for D2
autoreceptor function. Despite the fact that this possibility has not
been directly examined, it is unlikely that this is the case, because
in the mesencephalon as well as in many brain regions, GIRKs are
mainly expressed somatodendritically and are not involved in
terminal regulation [26,52,53,54]. Compatible with this hypoth-
esis, we found that blocking GIRK channels with barium failed to
enhance electrically-evoked DA overflow. In addition, barium
failed to reduce the ability of the D2 agonist quinpirole to inhibit
DA overflow in the striatum. Within this context however, it is
puzzling that tertiapin-Q, a selective antagonist of GIRK1/3
channels enhances electrically-evoked DA release in the guinea pig
striatal slice preparation [28]. This could perhaps reflect an age- or
species-difference in GIRK channel subtype expression or be due
to the ability of tertiapin-Q to also block other potassium channels
such as Ca
2+-activated potassium channels [55]. Considering the
questionable selectivity of this peptide, we have not included this
antagonist in the present study. However, we have previously
determined that tertiapin-Q fails to reduce the effect of quinpirole
on electrically-evoked DA overflow in rat striatal slices (single-
pulse evoked DA overflow was reduced by 68.767.4%, n=8,
p.0.05; Martel & Trudeau, unpublished observations).
Our results obtained with Kv blockers provide strong data in
favor of the presence of Kv1 channels and in particular Kv1.2,
Kv1.3 and perhaps Kv1.6 in the axonal terminals of DA neurons.
Our findings are compatible with those of a recent study
performed in mice and also suggesting the implication of Kv1.2
and Kv1.6 in the regulation of DA release [56]. The direct
enhancement of evoked DA release by MgTX in the present study
suggests the involvement of Kv1.3 channels [37,57,58]. Together
with the lack of effect of the Kv1.1 specific toxin DTX-K and the
effectiveness of TiTX, a blocker of Kv1.2, these results suggest that
Kv1.2 and Kv1.3 are particularly important. The reason for the
lack of additive effect of MgTX and TiTX on evoked DA overflow
and the variable effect of the mixed Kv1.1, Kv1.2 and Kv1.6
blocker a-DTX are unclear. However, the additive effects of a-
DTX and MgTX provides additional support for the involvement
of Kv1.2, Kv1.3 and perhaps Kv1.6 in regulating DA release
Figure 6. Evaluation of the role of GIRK and KATP channels in
regulating DA release. (A) Effect of 30 min perfusion of the GIRK
blocker barium (1 mM) (n=7;3) or the KATP blocker glibenclamide
(3 mM) (n=7;4) on DA overflow kinetics compared to control (n=8;6).
Data were normalized to the first 6 recordings (10 min) of their
respective control period (means 6 SEM). No significant effect was
noted. (B) Time-course of the experiment shown in A. DA was
electrically evoked at intervals of 2 min. Each group was normalized
to the first 6 recordings (10 min) of its respective control period (means
6 SEM). After a 10 min stabilization period, blockers were applied for
30 min. No significant effect of these two antagonists was noted.
Abbreviations: Glib, glibenclamide; Diazo, diazoxide.
doi:10.1371/journal.pone.0020402.g006
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Kv1 channels can form heteromers in the brain [63] and in
peripheral tissues [64], one possibility is that Kv1 channels in DA
neuron terminals form heteromers. For example, if Kv1.2/Kv1.3
heteromers are formed, these could in principle be blocked by
either TiTX or MxTX, explaining a lack of additivity. Likewise,
Kv1.2/Kv1.6 heteromers could be formed, that can be blocked by
either TiTX or a-DTX. In this context, the ability of a-DTX and
MgTX to additively enhance DA release might be due to the
simultaneous blockade of Kv1.2/Kv1.3 heteromers and of Kv1.2/
Kv1.6 heteromers. New experiments would be required to
compare the pharmacological sensitivity of monomers and
heteromers in a heterologous expression system. Our results are
in line with a previous demonstration that 4-AP, a broad-spectrum
IA-type potassium current blocker, can enhance DA release [27].
Although Kv1 channels have been demonstrated to be expressed
in varicose-like structures in the ventral striatum and various basal
ganglia nuclei [65], their presence in DA neurons and specific
expression in the axon terminals of DA neurons has not received
much attention. However, in a recent study performed in mice,
DA neurons have been shown to contain Kv1.1, Kv1.2, Kv1.3 and
Kv1.6 mRNA. Furthermore, Kv1.1, Kv1.2 and Kv1.6 immuno-
reactivity was found in TH-positive axonal varicosities in the
dorsal striatum [56]. Additional studies evaluating more directly
the localization of Kv1 channels in dopaminergic axons would be
useful to determine whether the channels are directly localized at
release sites or are found farther along the axonal membrane,
separate from the active zone.
Compatible with the results of experiments evaluating the effect
of Kv1 antagonists alone, we found that the same antagonists and
antagonist combinations that enhanced DA overflow also were
effective at reducing the effectiveness of the D2 agonist quinpirole
to inhibit DA overflow. The ability of a combined application of
TiTX and MgTX to additively reduce the presynaptic effect of
quinpirole is puzzling considering their lack of additivity in
enhancing DA overflow when used in the absence of quinpirole.
Although speculative, it is possible that the D2 receptor
preferentially regulates the function of Kv1 monomers. Here
again, additional experiments using a heterologous expression
system would be useful to clarify this issue. Nonetheless, based on
our experiments, we conclude that Kv1.2, Kv1.3 and perhaps
Kv1.6 are key regulators of presynaptic D2 receptor function and
that D2 receptor activation on dopaminergic axon terminals could
perhaps lead to an enhancement of Kv1 channel function. Our
results are consistent with previous work showing that D2 receptor
activation regulates a 4-AP-sensitive potassium current in DA
neurons [66] as well as in other cell types [67,68], although these
measurements were made at the cell body level.
Our finding that Kv1 potassium channel blockers reduce the
relative effectiveness of presynaptic D2 receptors can be
interpreted in two different ways. A first possibility is that Kv
channel regulation through the D2 receptor is directly required for
a substantial proportion of presynaptic D2 receptor function. For
example, a facilitation of the voltage-dependent activation of these
channels in response to D2 receptor stimulation could lead to
shortening of the action potential in the axon terminal, leading to
reduced opening of voltage-dependent Ca
2+ channels and DA
release. A second possibility is that Kv1 channels are not directly
regulated by the D2 receptor, but act instead as a gating
mechanism, influencing the impact of D2 receptor activation on
an alternate target, such as voltage-dependent Ca
2+ channels.
Considering on the one hand that Kv channels play a role in
maintaining membrane potential and modulating electrical
excitability in neurons [35], and on the other hand that G-protein
inhibition of N-type calcium channels is voltage-dependent [69], it
may be hypothesized that a blockade or reduction in Kv1 channel
function in axon terminals causes a modest depolarization of DA
terminals, which could reduce the ability of the D2 receptor to
inhibit N-type calcium channels. Arguing against such a
hypothesis of terminal depolarization, we found that direct
depolarization of terminals with elevated potassium ACSF failed
to significantly reduce D2-mediated inhibition of DA overflow.
Our previous demonstration that D2 receptor activation inhibits
exocytosis evoked independently of calcium channels in cultured
DA neurons through a mechanism blocked by 4-AP [70] also
speaks in favor of the hypothesis of a more direct role of Kv
channels. Moreover, it has been proposed that other terminal G-
protein-coupled receptors can inhibit neurotransmitter release by
acting directly through the regulation of potassium channels
[71,72,73,74]. However, further experiments are required to
evaluate whether the D2 receptor can directly regulate the
function of Kv1 channel subtypes in DA neurons. Whether
activation of Kv1 channels in response to D2 receptor stimulation
leads to spike narrowing or other changes in terminal excitability
will also need to be directly investigated.
A possible trivial explanation of the ability of Kv1 channel
blockers to reduce D2-mediated inhibition of DA release is that
the relative decrease in the effect of quinpirole in the presence of
the Kv1 blockers may simply result from the fact that the baseline
amount of release is increased in the presence of the toxins. There
would thus be a decrease in relative but not absolute DA release.
To address this possibility, we re-examined our data to look at
absolute levels of DA in a subset of experiments. We find that in
fact, in the presence of the Kv1 blockers, both the relative and the
absolute levels of DA release are significantly reduced in response
to quinpirole, thus validating our approach and interpretation. For
example, in control experiments without any antagonist, the
absolute decrease of evoked DA release induced by 1 mM
quinpirole was of 0.6960.09 mM (n=11). In comparison, in the
experiments with TiTX, the absolute decrease in DA release in
response to quinpirole was 0.4860.08 mM (n=6), a value
significantly smaller than in control experiments (p,0.05).
Similarly, in experiments with 4-AP, the absolute decrease of
evoked DA release induced by quinpirole was 0.3560.04 mM
(n=6), again a value significantly smaller that control (p,0.05).
In summary, our work underlines an important role for Kv1
potassium channels in regulating DA release as well as in
regulating the rapid inhibition of DA release in response to
presynaptic D2 receptor activation in dopaminergic axon
terminals of the dorsolateral striatum. By identifying a critical
family of ionic channels regulating DA release from axon
terminals, our findings may help to suggest novel strategies to
regulate DA release in the context of disease.
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